📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - in Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Shuchi Anand

From EverybodyWiki Bios & Wiki



Shuchi Anand
BornIndia
🎓 Alma materWashington University School of Medicine (MD)
Stanford University School of Medicine (MS)
💼 Occupation
🥚 TwitterTwitter=
label65 = 👍 Facebook

Shuchi Anand is an Indian-American nephrologist and clinical researcher investigating chronic kidney disease, tubulointerstitial disease, and global health. She the director of the Stanford Center for Tubulointerstitial Kidney Disease and an assistant professor of medicine at the Stanford University Medical Center. In 2020, Anand led a study that received widespread attention due to its estimate of COVID-19 infections in the United States, including the racial and economic disparities in infection rates.

Early life and education[edit]

Shuchi Anand was born in India and moved to the United States with her family at age 12. After observing disparities in healthcare on a visit back to India, Anand became interested in medicine.[1] She completed a medical degree at Washington University School of Medicine in 2006 and internal medicine training at the Brigham and Women's Hospital with Partners HealthCare and Harvard Medical School. She completed a master of science in clinical epidemiology and a nephrology fellowship at Stanford University School of Medicine.[2][3]

Career[edit]

Anand is the Director of the Stanford Center for Tubulointerstitial Kidney Disease[4] and an assistant professor of medicine at the Stanford University Medical Center.[3] Her clinical research areas include nephrology and tubulointerstitial disease, including a focus on patients in low-resource areas.[3][4] Her projects include collaborations with the Santa Clara Valley Medical Center and Emory University for the promotion of exercise programming for underserved populations, as well as the Center for Chronic Disease Control in India for the study of risk factors for kidney disease in South Asians, and the Kandy Hospital Sri Lanka for the investigation of chronic kidney disease of unknown etiology affecting agricultural communities.[5]

In 2012-2013, she was a Fogarty fellow, which allowed her to travel to India for a fellowship at the Centre for Chronic Disease Control (CCDC) to study chronic kidney disease (CKD) with her mentor, director Dr. Dorairaj Prabhakaran [Wikidata].[6] Her work included the Center for Cardiometabolic Risk Reduction in South Asia (CARRS) Surveillance Study, both intervewing subjects and analyzing data, and ultimately writing a 2015 paper as the lead author.[6]

After the Fogarty fellowship, Anand won an NIH career development grant to expand her work in India. Anand conducted mentored research on CKD in South Asians and found while the prevalence of CKD in urban India is similar to Indians who emigrated to the U.S., people in India are more likely to have worse outcomes.[6] Anand has studied 'chronic kidney disease of unknown cause or uncertain etiology' (CDKU) in India, Sri Lanka, and California.[7][8][9] In 2020, Anand won a Global Health Seed Grant from Stanford Global Health, to support research into whether natural farming in India supports kidney health.[10] In 2020, Anand also won a Diversity Chair Investigator Award to support her research, Kidney Disease in California’s Central Valley: Investigating the Disproportionate Risk in Agricultural Communities.[11]

In 2020, as director of the Stanford Center for Tubulointerstitial Kidney Disease, Anand was the lead author in a study published on September 25 in The Lancet that was the largest study at the time to measure COVID-19 antibody levels in the US.[12][13][14] Imperial College London professors Barnaby Flower and Christina Atchison wrote in an editorial published with the study that "Anand and colleagues deserve credit for pioneering a scalable sampling strategy that offers a blueprint for standardised national serosurveillance in the USA and other countries with a large haemodialysing population."[15] The research also uncovered racial and economic disparities in populations with COVID-19 antibodies,[16][17] highlighted the need for public health intervention to address the disparities,[18][19] and was described by epidemiologist Stephen Morse of the Mailman School of Public Health at Columbia University as important public health data, due to a lack of "reliable national data" when the study was published.[20] The study was published at a time when according to Newsweek, "Some U.S. officials have floated the concept of herd immunity as a possible strategy to manage the national outbreak,"[21] and according to Anand, "this study does not support that there is herd immunity."[22] For this work, Anand was named a Finalist in the 2021 Clinical Research Forum Top 10 Clinical Research Achievement Awards.[23] At the time of the publication of the study, Anand announced the intentions of researchers to continue monitoring study participants for months to help determine the effectiveness of COVID-19 mitigation tactics.[21][16][20]

Selected works[edit]

References[edit]

  1. ↑ Potash, Shana (February 2019). "Profile: Fogarty Fellow Dr Shuchi Anand studies chronic kidney disease CKD in India". NIH Fogarty International Center. Retrieved 2020-05-01. Unknown parameter |url-status= ignored (help) This article incorporates text from this source, which is in the public domain.
  2. ↑ "Shuchi Anand". kingcenter.stanford.edu. Retrieved 2020-05-01.
  3. ↑ 3.0 3.1 3.2 "Shuchi Anand's Profile". profiles.stanford.edu. Retrieved 2020-05-01.
  4. ↑ 4.0 4.1 "Center for Tubulointerstitial Kidney Disease". Stanford Medicine. Retrieved 11 March 2021.
  5. ↑ "Shuchi Anand". Stanford Health Care. Retrieved 12 March 2021.
  6. ↑ 6.0 6.1 6.2 Potash, Shana (February 2019). "Profile: Fogarty Fellow Dr Shuchi Anand studies chronic kidney disease CKD in India". Global Health Matters Newsletter, Vol. 18 (1). NIH. Fogarty International Center. Retrieved 9 March 2021.
  7. ↑ Oswald, Lucas Oliver. "5 Questions with Global Health Faculty Fellow Dr. Shuchi Anand on the environmental causes of an elusive kidney disease". Stanford Center for Innovation in Global Health. Retrieved 10 March 2021.
  8. ↑ Beyer, Rebecca (September 24, 2020). "Chasing the cause of chronic kidney disease". King Center for Global Development. Stanford University. Retrieved 12 March 2021.
  9. ↑ Erickson, Mandy (June 9, 2020). "Unexplained kidney disease in California more likely near agriculture". SCOPE. Standford Medicine. Retrieved 12 March 2021.
  10. ↑ "Congratulations to the 2020 Global Health Seed Grant Award Winners". Stanford Center for Innovation in Global Health. Retrieved 10 March 2021.
  11. ↑ "Four Projects Receive Diversity Chair Investigator Awards". Department of Medicine News. Standford Medicine.
  12. ↑ White, Tracie (September 28, 2020). "Fewer than 1 in 10 Americans have antibodies to coronavirus, study finds". Stanford University News Center. Retrieved 9 March 2021.
  13. ↑ Cortez, Michelle Fay (September 25, 2020). "Covid Immunity Remains Low With Under 10% of U.S. Adults Exposed". Bloomberg News. Retrieved 9 March 2021.
  14. ↑ Rothwell, Jonathan; Desai, Sonal (December 20, 2020). "How misinformation is distorting COVID policies and behaviors". The Brookings Institution. Retrieved 10 March 2021. Perhaps the best currently available estimate is from a large-scale sample of blood from dialysis patients who had to draw their blood for routine treatment (for kidney disease). After adjusting for the characteristics of the dialysis population Dr. Shuchi Anand and her coauthors estimated that 8.3% of the U.S. adult population was infected by COVID-19 through July of 2020.
  15. ↑ Kane, Andrea (September 25, 2020). "Fewer than 10% in the US have antibodies to the novel coronavirus". CNN. Retrieved 9 March 2021.
  16. ↑ 16.0 16.1 Cortez, Michelle Fay (September 28, 2020). "Covid Insights Come From Dialysis Patients". Bloomberg. Retrieved 10 March 2021.
  17. ↑ Foster, Robin; Mundell, E.J. (September 29, 2020). "Global Death Toll From COVID-19 Passes One Million". U.S. News and World Report. Retrieved 10 March 2021.
  18. ↑ Ghosh, Abantika (September 26, 2020). "Stanford study estimates fewer than 10% US adults had Covid antibodies in July". The Print. Retrieved 10 March 2021.
  19. ↑ Van Beusekom, Mary. "Less than 10% of US population has COVID-19 antibodies, data show". Center for Infectious Disease Research and Policy. University of Minnesota. Retrieved 10 March 2021.
  20. ↑ 20.0 20.1 Weintraub, Karen (September 28, 2020). "About 9% of Americans exposed to COVID-19 by midsummer. That's a long way from herd immunity". USA Today. Retrieved 10 March 2021.
  21. ↑ 21.0 21.1 Czachor, Emily (September 27, 2020). "National Coronavirus Antibody Study Suggests Herd Immunity 'Remains Out of Reach' in the U.S." Newsweek. Retrieved 9 March 2021.
  22. ↑ Feuer, Will (September 26, 2020). "Fewer than 10% of Americans show signs of past coronavirus infection, study finds". CNBC. Retrieved 13 March 2021.
  23. ↑ "Two Stanford Teams Named as Finalists for Clinical Research Awards". Department of Medicine News. Stanford Medicine. Retrieved 9 March 2021.
 This article incorporates public domain material from websites or documents of the National Institutes of Health.


This article "Shuchi Anand" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Shuchi Anand. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.


Retrieved from "https://en.everybodywiki.com/index.php?title=Shuchi_Anand&oldid=1487927"
License CC BY-SA 3.0
Powered by MediaWiki
Powered by Semantic MediaWiki